ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
National and subnational burden of neurological disorders in Iran, 1990 to 2021: results from the global burden of disease study 2021.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progressive Cognitive Decline and Pyramidal Signs in a Patient With a Novel Homozygous c.395A>T; p.Lys132Met Mutation in CHCHD2.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeurological disorders are a significant contributor to the global health burden. This study aims to provide a comprehensive assessment of the national and subnational burden of neurological disorders in Iran from 1990 to 2021 using the latest Global Burden of Disease (GBD) Study data.
methodsWe extracted data on incidence, prevalence, deaths, and disability-adjusted life years (DALYs) for major neurological disorders in Iran from the GBD 2021 study. The disorders were Alzheimer's disease (AD) and other dementias, headache disorders, idiopathic epilepsy, multiple sclerosis (MS), Parkinson's disease, motor neuron disease, and other neurological disorders.
resultsNeurological disorders affected 35.2 million individuals (95% uncertainty interval [UI]: 32.6-37.9 million) in 2021 in Iran. From 1990 to 2021, the age-standardized DALY and death rates neurological disorders in Iran decreased (-5.5% and - 8.9%, respectively). However, all-ages numbers increased substantially for all metrics. The five conditions with the highest age-standardized DALY rates per 100,000 in 2021 were headache disorders (716.3), AD and other dementias (473.6), idiopathic epilepsy (121.5), Parkinson's disease (73.8), and MS (28.0). Significant geographic variations were observed, with East Azarbayejan and Tehran consistently showing higher burdens.
conclusionsDespite improvements in age-standardized DALY rates, the absolute burden of neurological disorders in Iran has increased significantly from 1990 to 2021. Targeted interventions and resource allocation to address the growing challenge of neurological disorders in Iran are warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41622373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.